ArticleFrontiers in medicine2025
Variability in muscle function deficits and clinical identification of sarcopenic obesity in older adults with type 2 diabetes.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03560375. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of a Circuit Resistance Training, Empagliflozin or "Vegeterranean Diet" on Physical and Metabolic Function in Elderly Subjects With Type 2 Diabetes: a Study Protocol for a Randomized Control Trial (CEV-65 Trial)
Open the trial in the graphWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sarcopenic obesity (SO) is increasingly recognized as a major yet often overlooked complication in older adults-particularly those with type 2 diabetes (T2D)-and is linked to adverse events. SO evaluation requires muscle function tests [handgrip strength (HGS), knee extensor strength, chair-stand] and body composition. However, SO prevalence can vary widely depending on the muscle function test used, and these assessments are not routinely implemented in clinical care as they might be time-consuming. Aims: (1) Evaluate differences in the prevalence of altered muscle function using internationally accepted clinical guidelines among community-dwelling older adults with T2D; (2) to develop risk clusters for predicting increased SO probability; and (3) to develop an SO index based on routine clinical measures that differentiates individuals by their likelihood of having SO. Methods: Participants underwent comprehensive assessments of muscle function, including HGS, maximal knee extension strength, and chair stand test. Body composition was evaluated using bioelectrical impedance analysis to determine appendicular lean mass relative to body weight. Clinical data, including waist circumference, body mass index, prescription medications, metabolic markers, sex hormones, physical function tests, dietary intake, and physical activity, were collected using standardized protocols. Prevalence of altered muscle function and SO obesity was calculated using internationally accepted SO criteria. Results: Participated in the study 100 community dwelling older adults diagnosed with T2D (mean age: 69.75 ± 4.64). Altered muscle function prevalence ranged from 1% (HGS) to 92% (chair-stand). SO was present in 72% of the sample. Cluster analysis identified three SO severity groups: severe ( Conclusion: Among older adults with T2D, SO was prevalent, with substantial impairments in muscle function and body composition. Disease severity was primarily driven by alterations in appendicular lean mass and lower-limb strength, whereas handgrip strength showed limited discriminatory capacity. These findings highlight the importance of comprehensive functional and body composition assessment for older adults with T2D. Clinical trial registration: clinicaltrials.gov, identifier: NCT03560375.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.